HBV相关慢加急性肝衰竭免疫病理发病机制研究进展*

doi:10.3969/j.issn.1672-5069.2015.02.030

摘要/Abstract

摘要： 慢加急性肝衰竭（ACLF）是在慢性肝病基础上发生的急性肝功能失代偿。在我国,引起ACLF的首要病因是乙型肝炎病毒感染,其中病毒诱发的淋巴毒性T细胞活化和细胞因子大量分泌为代表的免疫病理损伤是肝衰竭发病的中心环节。本文将从抗原递呈、效应细胞的直接杀伤、宿主遗传背景、免疫相关细胞因子和免疫过激状态的抑制性调节等方面介绍HBV相关ACLF免疫病理发病机制的研究进展。

关键词: 慢加急性肝衰竭, 乙型肝炎, 免疫病理, 发病机制

Abstract: Acute-on-chronic liver failure （ACLF） refers to an acute decompensated liver function in patients with chronic liver diseases and the most common cause of ACLF in China is HBV infection. Activation of cytotoxic T lymphocytes and increased cytokines can cause immunopathogenetic injuries in liver tissues. This article mainly reviewed the immunopathogenesis progress of HBV related ACLF.

Key words: Acute-on-chronic liver failure, Hepatitis B, Immunopathogenesis

李晓东, 徐东平. HBV相关慢加急性肝衰竭免疫病理发病机制研究进展^*[J]. 实用肝脏病杂志, 2015, 18(3): 317-320.

Li Xiaodong, Xu Dongping. Immunopathogenesis of acute-on-chronic hepatitis B liver failure[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(3): 317-320.

参考文献

[1] 中华医学会感染病学分会肝衰竭与人工肝学组. 肝衰竭诊治指南（2012年版）. 实用肝脏病杂志,2013,16（3）：210-216.
[2] 黄湛镰,高志良. 肝衰竭的三重打击及治疗策略. 内科急危重症杂志,2014,20（3）：154-156.
[3] Atanley,E,van Drunen L,van den Hurk S. Future considerations for dendritic cell immunotherapy against chronic viral infections. Expert Rev Clin Immunol,2014,10（6）:801-813.
[4] Zhang Z,Zou ZS,Fu JL,et al. Severe dendritic cell perturbation is actively involved in the pathogenesis of acute-on-chronic hepatitis B liver failure. J Hepatol,2008,49（3）:396-406.
[5] Xing T,Li L,Cao H,et al. Altered immune function of monocytes in different stages of patients with acute on chronic liver failure. Clin Exp Immunol,2007,147（1）:184-188.
[6] Busca A,Kumar A. Innate immune responses in hepatitis B virus （HBV） infection. Virol J,2014,11:22.
[7] Schuch A,Hoh A,Thimme R. The role of natural killer cells and CD8（+） T cells in hepatitis B virus infection. Front Immunol,2014,5:258.
[8] Shabani Z,Bagheri M,Zare-Bidaki M,et al. NK cells in hepatitis B virus infection:a potent target for immunotherapy. Arch Virol,2014,159（7）:1555-1565.
[9] Conroy MJ,Mac N R,Grealy R,et al. Circulating CD56 natural killer cells and CD56 T cells that produce interferon-gamma or interleukin-10 are expanded in asymptomatic,E antigen-negative patients with persistent hepatitis B virus infection. J Viral Hepat,2014,doi:10.1111/jvh.12299. [Epub ahead of print].
[10] Kakimi K,Guidotti LG, Koezuka Y,et al. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med,2000,192（7）:921-930.
[11] Phillips S,Chokshi S,Riva A,et al. CD8（+） T cell control of hepatitis B virus replication:direct comparison between cytolytic and noncytolytic functions. J Immunol,2010,184（1）:287-295.
[12] Koh S,Bertoletti A. Viral hepatitis and serotonin:altering cytotoxic T-lymphocyte function in the liver. Expert Rev Vaccines,2009,8（1）:29-32.
[13] Zhang Z,Zhang JY,Wang LF,et al. Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection. J Gastroenterol Hepatol,2012,27（2）:223-230.
[14] Deng G,Zhou G,Zhai Y,et al. Association of estrogen receptor alpha polymorphisms with susceptibility to chronic hepatitis B virus infection. Hepatology,2004,40（2）:318-326.
[15] Xu Z,Liu Y,Liu L,et al. Association of interferon-gamma induced protein 10 promoter polymorphisms with the disease progression of hepatitis B virus infection in Chinese Han population. Plone One,2013,8（9）:e72799.
[16] Mao WL,Chen Y,Chen YM,et al. Changes of serum cytokine levels in patients with acute on chronic liver failure treated by plasma exchange. J Clin Gastroenterol,2011,45（6）:551-555.
[17] 赵攀,毕振华,王春亚. 急性肝衰竭患者血清炎性细胞因子水平分析. 实用肝脏病杂志,2014,17（1）：63-64.
[18] Wang K,Wu ZB,Ye YN,et al. Plasma interleukin-10:A likely predictive marker for hepatitis B virus-related acute-on-chronic liver failure. Hepat Mon,2014,14（7）:e19370.
[19] Xu H,Li H,Qu Y,et al. High mobility group box 1 release from cholangiocytes in patients with acute-on-chronic liver failure. Exp Ther Med,2014,8（4）:1178-1184.
[20] Zhang JJ,Fan YC,Zhang ZH,et al. Methylation of suppressor of cytokine signalling 1 gene promoter is associated with acute-on-chronic hepatitis B liver failure. J Viral Hepat,2014,doi:10.1111/jvh.12286. [Epub ahead of print].
[21] Liang XS,Li CZ,Zhou Y,et al. Changes in circulating Foxp3（+） regulatory T cells and interleukin-17-producing T helper cells during HBV-related acute-on-chronic liver failure. World J Gastroenterol,2014,20（26）:8558-8571.
[22] Hu X,Ma S,Huang X,et al. Interleukin-21 is upregulated in hepatitis B-related acute-on-chronic liver failure and associated with severity of liver disease. J Viral Hepat,2011,18（7）:458-467.
[23] Zou Z,Li B,Xu D,et al. Imbalanced intrahepatic cytokine expression of interferon-gamma,tumor necrosis factor-alpha,and interleukin-10 in patients with acute-on-chronic liver failure associated with hepatitis B virus infection. J Clin Gastroenterol, 2009,43（2）:182-190.
[24] Jin X,Zimmers TA, Perez EA,et al. Paradoxical effects of short-and long-term interleukin-6 exposure on liver injury and repair. Hepatology,2006,43（3）:474-484.
[25] Lang PA,Lang KS,Xu HC,et al. Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8 + T-cell immunity. Proc Natl Acad Sci U S A,2012,109（4）:1210-1215.
[26] Waggoner SN,Cornberg M,Selin LK,et al. Natural killer cells act as rheostats modulating antiviral T cells. Nature,2012,481（7381）:394-398.
[27] Cook KD,Whitmire JK. The depletion of NK cells prevents T cell exhaustion to efficiently control disseminating virus infection. J Immunol,2013,190（2）:641-649.
[28] Li X,Wang Y,Chen Y. Cellular immune response in patients with chronic hepatitis B virus infection. Microb Pathog,2014,74C:59-62.
[29] Francisco LM,Salinas VH,Brown KE,et al. PD-L1 regulates the development,maintenance,and function of induced regulatory T cells. J Exp Med,2009,206（13）:3015-3029.
[30] Radziewicz H,Hanson HL,Ahmed R,et al. Unraveling the role of PD-1/PD-L interactions in persistent hepatotropic infections:potential for therapeutic application. Gastroenterology,2008,134（7）:2168-2171.
[31] Zhang Z,Zhang JY,Wherry EJ,et al. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology,2008,134（7）:1938-1949,1949.e1-3.
[32] Liu W,Putnam AL,Xu YZ,et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4 + T reg cells. J Exp Med,2006,203（7）:1701-1711.
[33] Zhou L,Lopes JE,Chong MM,et al. TGF-beta-induced Foxp3 inhibits T（H）17 cell differentiation by antagonizing RORgammat function. Nature,2008,453（7192）:236-240.
[34] Dong X,Gong Y,Zeng H,et al. Imbalance between circulating CD4 + regulatory T and conventional T lymphocytes in patients with HBV-related acute-on-chronic liver failure. Liver Int,2013,33（10）:1517-1526.
[35] Niu YH,Yin DL,Liu HL,et al. Restoring the Treg cell to Th17 cell ratio may alleviate HBV-related acute-on-chronic liver failure. World J Gastroenterol,2013,19（26）:4146-4154.

HBV相关慢加急性肝衰竭免疫病理发病机制研究进展^*

Immunopathogenesis of acute-on-chronic hepatitis B liver failure

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[2]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[5]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[6]	马丽英, 沈利娟. 妊娠后期应用替诺福韦治疗血清HBV高载量孕妇阻断HBV母婴传播的疗效及安全性分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 836-839.
[7]	潘美民, 李文娟, 蒋芳清, 杨丽晖, 谭永卫, 何娟, 阮建文, 蔡春琳. 慢性丙型肝炎患者血清IL-17A、FGF和IL-7水平与丙型肝炎病毒感染自发清除临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 840-843.
[8]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[9]	张瑞, 王剑, 陈世耀. 肝硬化门脉高压症并发血栓形成机制和治疗研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 930-933.
[10]	梁巨波, 苗琪, 马雄. 胆管细胞型胆汁淤积诊治进展[J]. 实用肝脏病杂志, 2019, 22(6): 941-943.
[11]	杜科业, 杨东亮, 刘嘉. 慢性乙型肝炎与调节性T细胞研究进展^*[J]. 实用肝脏病杂志, 2019, 22(5): 613-616.
[12]	廖桂婵, 彭颉, 张小勇. 肝细胞介导的天然免疫应答参与控制乙型肝炎病毒感染^*[J]. 实用肝脏病杂志, 2019, 22(5): 617-619.
[13]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[14]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[15]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.